Cue Biopharma, Inc.·4

Jun 8, 4:25 PM ET

Camardo Daniel A. 4

Research Summary

AI-generated summary

Updated

Cue Biopharma Director Daniel Camardo Receives 1,626-Share Award

What Happened

  • Director Daniel A. Camardo received a derivative equity award for 1,626 shares on 2026-05-30. The reported acquisition price was $0.00, so no cash was paid and the reported value is $0. This is a grant/award (code A) — typically a compensation grant rather than an open-market purchase or sale.

Key Details

  • Transaction date: 2026-05-30; filing date (Form 4): 2026-06-08. The filing appears to be later than the standard two-business-day reporting window.
  • Amount: 1,626 shares acquired as a derivative award; reported price $0.00; total reported value $0.
  • Shares owned after the transaction: Not specified in the provided filing details.
  • Footnote: The underlying shares vest over three years — one-third vests on the one-year anniversary of the grant, with the remaining shares vesting in eight equal quarterly installments (see footnote F1).
  • Transaction type: A = Award/Grant of a derivative instrument (likely RSUs or stock options); not an immediate cash purchase or sale.

Context

  • This was a compensation-related award, which is common for directors and does not necessarily signal a buy or sell decision by the insider. The award vests over time, so any future sales or exercises will be reported separately. The late filing may delay transparency for investors tracking insider activity.